MabVax Therapeutics to Hold Conference Call to Provide Corporate Update On Monday, November 14, 2016

Interim safety and imaging results from Phase I clinical trials in HuMab-5B1 antibody development programs to be discussed at time of conference call

SAN DIEGO, Nov. 14, 2016 /PRNewswire/ -- MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX), today will hold a conference call after the U.S. financial markets close to discuss third quarter financial results and interim safety and imaging results from phase I clinical trials in HuMab-5B1 antibody development programs.  Below are details for the call.

Conference Call Information

When: November 14, 2016, 4:15 p.m. ET
Dial-in: (877) 407-8293 or (201) 689-8349
Conference ID: MabVax Therapeutics Third Quarter 2016 Conference Call

Please join the conference call at least 10 minutes early to register.  A replay of the conference call will be available for 2 weeks shortly after the call.  To access the replay, please dial 877-660-6853 or 201-612-7415.  Conference ID: 13649739.

About MabVax Therapeutics Holdings, Inc.

MabVax Therapeutics Holdings, Inc. is a clinical-stage biotechnology company focused on the development of antibody-based products to address unmet medical needs in the treatment of cancer.  MabVax has discovered a pipeline of human monoclonal antibody products based on the protective immune responses generated by patients who have been vaccinated against targeted cancers with the Company's proprietary vaccines.  MabVax's HuMab-5B1 antibody is fully human and was discovered from the immune response of cancer patients vaccinated with an antigen-specific vaccine during a Phase I trial at Memorial Sloan Kettering Cancer Center, or MSK.   The antigen the antibody targets is expressed on more than 90% of pancreatic cancers making the antibody potentially broadly applicable to most patients suffering from this type of cancer.   Additional information is available at


Robert Haag, Managing Director
IRTH Communications


To view the original version on PR Newswire, visit:

SOURCE MabVax Therapeutics Holdings, Inc.